Rhumbline Advisers raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.4% during the second quarter, Holdings Channel reports. The institutional investor owned 365,823 shares of the medical equipment provider’s stock after buying an additional 1,589 shares during the period. Rhumbline Advisers’ holdings in Zimmer Biomet Holdings were worth $46,972,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. DekaBank Deutsche Girozentrale raised its position in Zimmer Biomet Holdings by 0.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 135,569 shares of the medical equipment provider’s stock valued at $17,446,000 after buying an additional 1,000 shares in the last quarter. First Trust Advisors LP raised its position in Zimmer Biomet Holdings by 21.4% in the second quarter. First Trust Advisors LP now owns 107,055 shares of the medical equipment provider’s stock valued at $13,746,000 after buying an additional 18,863 shares in the last quarter. Boston Partners raised its position in Zimmer Biomet Holdings by 3.3% in the second quarter. Boston Partners now owns 1,277,442 shares of the medical equipment provider’s stock valued at $164,024,000 after buying an additional 40,826 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Zimmer Biomet Holdings by 1.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 669,622 shares of the medical equipment provider’s stock valued at $85,980,000 after buying an additional 7,273 shares in the last quarter. Finally, Trent Capital Management Inc. NC acquired a new position in Zimmer Biomet Holdings during the second quarter valued at $5,266,000. Hedge funds and other institutional investors own 83.62% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) opened at 111.70 on Friday. The firm has a market cap of $22.59 billion, a P/E ratio of 31.81 and a beta of 1.20. The company has a 50 day moving average price of $124.93 and a 200-day moving average price of $121.26. Zimmer Biomet Holdings, Inc. has a 52-week low of $95.63 and a 52-week high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same quarter in the prior year, the company earned $2.02 EPS. The company’s revenue was up 1.1% on a year-over-year basis. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.86%. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.

WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-nysezbh-stake-increased-by-rhumbline-advisers/1478310.html.

Several research firms have weighed in on ZBH. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a report on Tuesday. BidaskClub lowered Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BMO Capital Markets lifted their target price on Zimmer Biomet Holdings from $136.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, July 28th. Leerink Swann lifted their target price on Zimmer Biomet Holdings from $141.00 to $146.00 and gave the stock an “outperform” rating in a report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $137.00 target price on Zimmer Biomet Holdings and gave the stock a “buy” rating in a report on Friday, July 28th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $136.90.

In related news, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Tony W. Collins sold 16,986 shares of the company’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The disclosure for this sale can be found here. Corporate insiders own 1.07% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.